Corbus Pharmaceuticals Holdings Inc. closed $42.39 short of its 52-week high ($61.90), which the company reached on July 31st ...

This was the stock's third consecutive day of losses.

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

The US stock markets opened lower on Friday, September 20, as investors held back after a jump in the previous session, which ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE: NKE ), which rose 6.84% or 5.54 ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...